Anti-Mouse B220 Antibody (RA3.3A1/6.1)
Based on 1 Customer Validation
Anti-Mouse B220 Antibody (RA3.3A1/6.1) is a rat-derived IgM type antibody inhibitor, targeting to mouse B220. Anti-Mouse B220 Antibody (RA3.3A1/6.1) can deplete B cells. Anti-Mouse B220 Antibody (RA3.3A1/6.1) can be used for the researches of cancer and immunology, such as 4T1 and B16 tumor.
For research use only. We do not sell to patients.
- Purity : ≥95%
- Molecular Weight:150 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
Isotype
Rat IgM
Recommend Isotype Controls
Species Reactivity
Mouse
IC50 & Target
B220
In Vitro
The antibody framework is stable, specific and adaptable, and has the ability to bind both antigens and endogenous immune receptors. Monoclonal antibodies have several derivatives, including bispecific antibodies, antibody-drug conjugates, and antibody fragments, and have significant effects in fields such as immunology and oncology. When designing inhibitory antibodies, considerations include identification of antigen-specific variable regions, choice of expression system, use of multispecific formats, and antibody derivatives based on fragmentation, oligomerization, or conjugation with other functional moieties[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Anti-Mouse B220 Antibody (RA3.3A1/6.1) (300 μg, i.p., three weeks before tumor inoculation and every 5 days thereafter) depletes B cells and accelerates tumor development and delays or prevents tumor rejection in B16 tumor mice[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:4T1 tumor mice[1]
-
Dosage:400 μg
-
Administration:Intraperitoneally injection, at days 3, 10 and 18
-
Result:Depleted B220+ cells.
Almost completely abrogated lung metastases.
-
Animal Model:B16 tumor mice models[2]
-
Dosage:300 μg
-
Administration:Intraperitoneally injection, three weeks before tumor inoculation and every 5 days thereafter
-
Result:Depleted B cells.
Accelerated tumor development.
Delayed or prevented tumor rejection.
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Product Image
Application
in vivo B cell depletion; in vitro B cell negative selection
Chemical Information
-
Appearance Liquid
-
Molecular Weight 150 kDa
-
Color Colorless to light yellow
-
SMILES
[Anti-Mouse B220 Antibody (RA3.3A1/6.1)]
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (261 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Olkhanud PB, et al. Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4⁺ T cells to T-regulatory cells. Cancer Res. 2011 May 15;71(10):3505-15. [Content Brief]
[2]. Carmi Y, et al. Allogeneic IgG combined with dendritic cell stimuli induce antitumour T-cell immunity. Nature. 2015 May 7;521(7550):99-104. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Anti-Mouse B220 Antibody (RA3.3A1/6.1) Related Classifications
HY-P990299 Related Classifications
Powered by Bioz